360 results on '"Fiorentino, Michelangelo"'
Search Results
2. Overview of liquid biopsy
3. Contributors
4. β‐Catenin alterations in testicular Leydig cell tumour: a immunohistochemical and molecular analysis
5. New entity of adult ultra-short coeliac disease: the first international cohort and case–control study
6. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis
7. Analysis of GATA3 and FOXA2 expression suggests that downregulation of genes involved in the maintenance of a mature yolk sac tumor phenotype may underlie sarcomatoid transformation
8. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
9. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT
10. Cohort profile: the Turin prostate cancer prognostication (TPCP) cohort
11. TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis
12. “Paradoxical” p16 overexpression in cutaneous melanoma: Molecular and immunohistochemical analysis of a rare phenomenon with a focus on cell cycle regulatory molecules
13. An Apparent Diffusion Coefficient-Based Machine Learning Model Can Improve Prostate Cancer Detection in the Grey Area of the Prostate Imaging Reporting and Data System Category 3: A Single-Centre Experience
14. Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer
15. Influence of Neighborhood Social and Natural Environment on Prostate Tumor Histology in a Cohort of Male Health Professionals
16. Supplementary Figure from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
17. Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
18. Abstract 737: Variation in prognostic value of Gleason score for lethal prostate cancer using time-varying area under the curve
19. Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
20. Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
21. Data from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
22. Supplementary Figure 1 from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum
23. Supplementary Figure 4 from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum
24. Supplementary Tables 1-12, Supplementary Figures 1-2 from The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer
25. Supplementary Figure 2 from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum
26. Supplementary Table and Figure Legends from The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer
27. Supplementary Tables 1-12, Supplementary Figures 1-2 from The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer
28. Supplementary Figure 3 from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum
29. Data from The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer
30. Supplementary Tables 1-5, Supplementary Figures 1-3 from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
31. Supplementary Data from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum
32. Data from The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer
33. Data from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum
34. Supplementary Table 1 from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum
35. Supplementary Tables 1-5, Supplementary Figures 1-3 from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
36. Supplementary Data from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum
37. Supplementary Figure 3 from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum
38. Supplementary Table and Figure Legends from The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer
39. Supplementary Table 1 from Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum
40. Supplementary Figure 3 from Prognostic Utility of a New mRNA Expression Signature of Gleason Score
41. Supplementary Table 4 from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer
42. Supplementary Figure 1 from The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis
43. Supplementary Figure 2 from Prognostic Utility of a New mRNA Expression Signature of Gleason Score
44. Supplementary Table 3 from The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis
45. Supplementary Table 3 from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer
46. Data from Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer
47. Supplementary Table 3 from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer
48. Supplementary Table 1 from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer
49. Supplementary Table 4 from Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer
50. Data from The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.